Nordisk
-
USA
Novo Nordisk (NVO) Q1 2026 earnings: Wegovy sales jump
People pass by the sign for the annual general meeting of Novo Nordisk at the entrance of the meeting hall…
Read More » -
USA
Novo Nordisk Wegovy pill beating Eli Lilly Foundayo early
Still life of new Wegovy semaglutide tablets on white background. It is a prescription medication used in conjunction with a…
Read More » -
USA
Novo Nordisk partners with OpenAI as AI drug discovery hopes mount
People pass by the sign for the annual general meeting of Novo Nordisk at the entrance of the meeting hall…
Read More » -
USA
Eli Lilly market share drops, Novo Nordisk holds firm as generic weight-loss drugs flood India
Eli Lilly and Novo Nordisk logos. Mike Blake | Tom Small | Reuters Market share of India’s most popular weight…
Read More » -
USA
Novo Nordisk stock rises after Wegovy recommended by UK’s drug price regulator
Michael Siluk | UCG | Universal Images Group | Getty Images Novo Nordisk It rose as much as 4 percent…
Read More » -
USA
Novo Nordisk launches Wegovy subscription for GLP-1 obesity drugs
Wegovy semaglutide tablets. Michael Siluk | Universal Images Group | Getty Images Novo Nordisk On Tuesday, Wegovy launched a multi-month…
Read More » -
USA
India is launching cheap, weight-loss drugs and Novo Nordisk is betting on its brands to stay on top
In this photo taken in Brussels, Belgium, on August 9, 2025, the Novo Nordisk logo is seen with tablets, capsules…
Read More » -
USA
Novo Nordisk failed to report deaths of weight-loss drug patients
Novo Nordisk, maker of the popular weight-loss drugs Ozempic and Wegovy, is under fire from the federal government for failing…
Read More » -
USA
Novo Nordisk to slash Wegovy, Ozempic U.S. list prices by up to 50%
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, on February…
Read More » -
USA
Novo Nordisk stock falls as weight loss drug fails to beat Eli Lilly
Novo Nordisk The stock fell 15% on Monday after it said its next-generation weight-loss drug failed to meet its core…
Read More »